See Kay Choong
Division of Respiratory and Critical Care Medicine, Department of Medicine, National University Hospital, Singapore 119228, Singapore.
Vaccines (Basel). 2023 Dec 2;11(12):1809. doi: 10.3390/vaccines11121809.
Respiratory syncytial virus (RSV) poses a significant burden on public health, causing lower respiratory tract infections in infants, young children, older adults, and immunocompromised individuals. Recent development and licensure of effective RSV vaccines provide a promising approach to lessening the associated morbidity and mortality of severe infections. This narrative review aims to empower clinicians with the necessary knowledge to make informed decisions regarding RSV vaccination, focusing on the prevention and control of RSV infections, especially among vulnerable populations. The paper explores the available RSV vaccines and existing evidence regarding their efficacy and safety in diverse populations. Synthesizing this information for clinicians can help the latter understand the benefits and considerations associated with RSV vaccination, contributing to improved patient care and public health outcomes.
呼吸道合胞病毒（RSV）给公共卫生带来了沉重负担，可导致婴儿、幼儿、老年人和免疫功能低下者发生下呼吸道感染。近期有效的RSV疫苗的研发和获批为降低严重感染相关的发病率和死亡率提供了一种有前景的方法。本叙述性综述旨在为临床医生提供必要的知识，以便就RSV疫苗接种做出明智的决策，重点关注RSV感染的预防和控制，尤其是在脆弱人群中。本文探讨了现有的RSV疫苗以及关于其在不同人群中的疗效和安全性的现有证据。为临床医生综合这些信息有助于他们理解与RSV疫苗接种相关的益处和注意事项，从而改善患者护理和公共卫生结果。
